Clinical trial
A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers
NCT03651349 is registered in ClinicalTrials.gov with Everfront Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers
- Lead sponsor
- Everfront Biotech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- February 1, 2021
- Completion date
- June 30, 2028
- Enrollment
- 56 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.